Current problems in cancer. Case reports最新文献_第10页

A case of hepatic dysfunction from crizotinib followed by treatment with entrectinib 克唑替尼治疗肝功能障碍1例

Current problems in cancer. Case reports Pub Date : 2023-10-02 DOI: 10.1016/j.cpccr.2023.100262

Takahito Mizuno , Satoshi Hagimoto , Takumi Umemura , Mariko Higashikawa , Takamasa Sakai , Kouichi Tanabe , Fumiko Ohtsu , Tetsuya Yamada , Tomoki Kimura

{"title":"A case of hepatic dysfunction from crizotinib followed by treatment with entrectinib","authors":"Takahito Mizuno , Satoshi Hagimoto , Takumi Umemura , Mariko Higashikawa , Takamasa Sakai , Kouichi Tanabe , Fumiko Ohtsu , Tetsuya Yamada , Tomoki Kimura","doi":"10.1016/j.cpccr.2023.100262","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100262","url":null,"abstract":"<div><h3>Background</h3><p>Information regarding the safety of entrectinib for previously treated patients and patients with hepatic dysfunction is limited. This is the first case report of treatment modification attributable to hepatic dysfunction caused by crizotinib.</p></div><div><h3>Patients</h3><p>A 76-year-old Japanese woman was referred to the Department of Respiratory Medicine and Allergy after a computed tomography (CT) scan at the time of thyroid surgery. The CT scan revealed an enlarged right upper lobe nodule. After careful examination, she was diagnosed with T3N2M1c stage IV ROS1-positive lung adenocarcinoma; therefore, crizotinib (500 mg/day) was prescribed. On day 861 of treatment, crizotinib was discontinued because of repeatedly observed increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Approximately 2 weeks after crizotinib was discontinued, treatment was restarted with entrectinib 600 mg/day.</p></div><div><h3>Conclusions</h3><p>Entrectinib was prescribed because crizotinib caused hepatic dysfunction; however, the patient experienced grade 3 neutropenia and the creatinine phosphokinase (CPK) levels increased. After the dose reduction, she was able to continue treatment safely, without further worsening of the primary tumor or hepatic dysfunction. Therefore, entrectinib may be an option for patients who need treatment modification because of crizotinib-induced hepatic dysfunction. Increased CPK is a previously unknown adverse event occurring with entrectinib. This information is essential to risk management plans involving this drug. Further information regarding increased CPK and rhabdomyolysis occurring in patients treated with entrectinib is needed.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"12 ","pages":"Article 100262"},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49846525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Central nervous system manifestations as initial presentation of plasma cell disorders: Differential management of 3 cases based on disease extent 中枢神经系统表现为浆细胞疾病的最初表现：3例基于疾病程度的差异化处理

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100247

Kyle McGrath , Graeme A. Fenton , Robert P. Seifert , Keith R. Peters , John W. Hiemenz , Erin A. Dean

引用次数: 0

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis 布伦妥昔单抗韦多汀在血液透析中长期安全应用于一例经典霍奇金淋巴瘤患者

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100249

Aimee Schad , Abhinandan R Pakanati , Susan Woelich , Abhishek Chilkulwar

引用次数: 0

Orbital cellulitis and massive chemosis as first sign of a cilio-choroidal malignant melanoma without extraocular extension: A case report 眼眶蜂窝织炎和大量化脓是无眼外扩展的纤毛-脉络膜恶性黑色素瘤的第一个征象:1例报告

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100253

Matteo Mario Carlà , Carmela Grazia Caputo , Maria Grazia Sammarco , Federico Giannuzzi , Chiara Fantozzi , Gustavo Savino , Maria Antonietta Blasi , Monica Maria Pagliara

{"title":"Orbital cellulitis and massive chemosis as first sign of a cilio-choroidal malignant melanoma without extraocular extension: A case report","authors":"Matteo Mario Carlà , Carmela Grazia Caputo , Maria Grazia Sammarco , Federico Giannuzzi , Chiara Fantozzi , Gustavo Savino , Maria Antonietta Blasi , Monica Maria Pagliara","doi":"10.1016/j.cpccr.2023.100253","DOIUrl":"10.1016/j.cpccr.2023.100253","url":null,"abstract":"<div><h3>Purpose</h3><p>To describe a case of cilio-choroidal melanoma presenting as aseptic orbital cellulitis with massive conjunctival chemosis.</p></div><div><h3>Methods</h3><p>Case report.</p></div><div><h3>Results</h3><p>A 51-year-old man with a left retro-iris pigmented lesion had acute lid edema, conjunctival chemosis, and extensive hyphema. Ultrasound revealed a large, lobulated, wide-base choroidal-starting lesion affecting the ciliary bodies and vitreous chamber. MRI revealed low-intermediate T2-signal and intermediate-high T1-signal, with substantial post-contrastographic enhancement. After one week of systemic corticosteroids, the chemosis reduced significantly, and the patient was referred for enucleation, even without histologic confirmation. Post-surgical histopathology found 90% necrotic tissue, few viable cells, and no scleral or vascular invasion, with genetic analysis showing monosomy of chromosome 3 and 8q gain.</p></div><div><h3>Conclusion</h3><p>Choroidal melanoma, particularly if necrotic, may occasionally present as aseptic orbital cellulitis, even without extraocular spread.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100253"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46535821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leptomeningeal carcinomatosis in a patient with PALB2-mutated pancreatic adenocarcinoma: A case report and review of the literature palb2突变的胰腺腺癌患者的轻脑膜癌:1例报告和文献复习

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100251

Dylan D. Walker , Benjamin G. Kubas , Guy T. Clifton , Jason K. Burris , Matthew J. Rendo

引用次数: 0

Malignant transformation of mature cystic teratoma involving bowel: A case report 累及肠道的成熟囊性畸胎瘤恶性转化1例报告

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100261

Sarah Thappa , Sara Spielman , Naixin Zhang , Janira Navarro Sanchez , Ashlee Smith , Richard Moore , Rachael Rowswell-Turner , Cynthia Angel , Brent DuBeshter

引用次数: 0

Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report 一种新的CGN-RET融合突变对奥西替尼和塞尔帕卡替尼联合治疗有良好反应，导致晚期EGFR突变NCSLC对奥西替尼治疗产生耐药性，病例报告

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100246

Hamid Mirshahidi , Sue Min Sophia Kwon , Alberto Romagnolo , Kiwon Park , Adam Hagele

引用次数: 0

A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report 在免疫检查点抑制的情况下，一个独特的蛋白质丢失性肠病病例报告

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100252

Ezra Bernstein , James Weinberger , Avi Baskin , Eesha Balar , Victor Adorno Febles , Arjun V. Balar

{"title":"A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report","authors":"Ezra Bernstein , James Weinberger , Avi Baskin , Eesha Balar , Victor Adorno Febles , Arjun V. Balar","doi":"10.1016/j.cpccr.2023.100252","DOIUrl":"10.1016/j.cpccr.2023.100252","url":null,"abstract":"<div><p>Protein-losing enteropathy (PLE) is a well described entity, typically associated with autoimmune disorders such as Systemic Lupus Erythematosus (SLE). However, there is only one prior case reported on the association between PLE and the use of immune checkpoint inhibitors. We describe a case of PLE presenting in a patient in their 70’s with muscle-invasive urothelial bladder cancer that developed while on treatment with pembrolizumab, radiation and gemcitabine for her cancer. The patient presented initially with progressive edema and hypoalbuminemia, and diffuse small bowel thickening on CT imaging without associated upper or lower gastrointestinal symptoms. Endoscopy with biopsy was performed demonstrating normal gastric and small bowel epithelium. A stool test for alpha-1-antitrypsin demonstrated increased clearance consistent with fecal protein loss and a diagnosis of PLE, presumed immune-related. She was promptly initiated on systemic corticosteroids with brisk resolution in her symptoms and normalization of serum albumin levels.</p></div><div><h3>Insights</h3><p>This case highlights a rare immune-related adverse event, PLE, that should be considered in patients who develop hypoalbuminemia and its clinical sequelae after immune checkpoint inhibition therapy without evidence of colitis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43036372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast metastasis from primary lung cancer and its association with ablative radiotherapy: A case report 原发性肺癌乳腺转移及其与消融放疗的关系:1例报告

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100256

Matthew E. Volpini, Jason R. Pantarotto

{"title":"Breast metastasis from primary lung cancer and its association with ablative radiotherapy: A case report","authors":"Matthew E. Volpini, Jason R. Pantarotto","doi":"10.1016/j.cpccr.2023.100256","DOIUrl":"10.1016/j.cpccr.2023.100256","url":null,"abstract":"<div><p>This is a case report of a patient with PD-L1 positive metastatic lung adenocarcinoma who underwent palliative and ablative dose radiotherapy directed to metastatic axillary nodal disease and went on to develop localized followed by diffuse breast and cutaneous metastases. This case serves as an example of the potential utility of ablative dose radiotherapy for controlling sites of progression and highlights the risk of ablative radiotherapy for altering lymphatic drainage and promoting retrograde spread of disease. Given the increased incidence of oligometastatic NSCLC, and the increased utilization of ablative dose radiotherapy to treat metastatic sites in this clinical setting, we believe that this article may inform clinical practice. Our results provide additional support for the utility of ablative dose radiotherapy for this patient population and highlight the need for clinicians to employ a patient-specific approach when deciding on treatment, understanding that the use ablative doses of radiotherapy may provide a better chance for radiologic control, but may come at the cost of an increased risk of altered lymphatic drainage and retrograde spread of disease. The case was overseen by a multidisciplinary team consisting of primary care, medical and radiation oncologists as well as palliative care physicians.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100256"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43131067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful complete resection and recurrence-free outcome in renal cell carcinoma with vena cava tumor thrombus: Neoadjuvant immune checkpoint inhibitor (ICI)-based combination therapies 肾细胞癌伴腔静脉肿瘤血栓的成功完全切除和无复发结局:基于新辅助免疫检查点抑制剂(ICI)的联合治疗

Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI: 10.1016/j.cpccr.2023.100260

Hirofumi Yoshino, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Shuichi Tatarano, Yasutoshi Yamada, Hideki Enokida

{"title":"Successful complete resection and recurrence-free outcome in renal cell carcinoma with vena cava tumor thrombus: Neoadjuvant immune checkpoint inhibitor (ICI)-based combination therapies","authors":"Hirofumi Yoshino, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Shuichi Tatarano, Yasutoshi Yamada, Hideki Enokida","doi":"10.1016/j.cpccr.2023.100260","DOIUrl":"10.1016/j.cpccr.2023.100260","url":null,"abstract":"<div><p>Treatment of advanced renal cell carcinoma (RCC) typically involves surgery, even in challenging cases (ie, inferior vena cava [IVC] tumor thrombus, stage 3b [T3b] disease). Although tyrosine kinase inhibitor (TKI)-based neoadjuvant therapy shrinks primary tumors for resection, its benefit for T3b disease is limited, and no guidelines recommend it. Immune checkpoint inhibitor (ICI) combinations and TKIs plus ICIs provide new options for unresectable/metastatic RCC, but reports on ICI-based neoadjuvant therapy for T3b disease are scarce, and none describes survival after cytoreductive nephrectomy. In the present study, we have experienced three cases of advanced RCC with level 2 IVC thrombus, in which neoadjuvant therapy with different types of ICI-based combination therapies was utilized. This approach resulted in significant tumor reduction, regression of thrombus, and successful laparoscopic radical nephrectomy. Pathological analysis confirmed complete responses and no residual carcinoma, including metastatic sites. Notably, no recurrence was observed over 1.5 years in all cases. ICI-based neoadjuvant therapy may facilitate curative resection and prolong progression-free survival in advanced RCC. ICI-based neoadjuvant therapy may facilitate curative resection and prolong progression-free survival in advanced RCC.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100260"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43258239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0